Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Pentoxifylline Suppresses Transduction by HIV-1-Based Vectors

Smith J.A. · Nunnari G. · Preuss M. · Pomerantz R.J. · Daniel R.

Author affiliations

Division of Infectious Diseases, Center for Human Virology, Thomas Jefferson University, Philadelphia, Pa., USA

Related Articles for ""

Intervirology 2007;50:377–386

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: January 23, 2007
Accepted: February 08, 2007
Published online: October 15, 2007
Issue release date: October 2007

Number of Print Pages: 10
Number of Figures: 6
Number of Tables: 0

ISSN: 0300-5526 (Print)
eISSN: 1423-0100 (Online)

For additional information: https://www.karger.com/INT

Abstract

Pentoxifylline, a caffeine-related compound, was shown to suppress human immunodeficiency virus type 1 (HIV-1) replication. This effect is thought to be mediated by inhibition of tumor necrosis factor-alpha (TNFα)-mediated long-terminal repeat (LTR)-driven expression. We now demonstrate that pentoxifylline efficiently inhibits transduction by HIV-1-based vectors. This latter effect is independent of LTR-driven expression, and correlates with a reduced efficiency of the completion of the integration process in infected cells. Finally, the effect of pentoxifylline is dramatically reduced in cells expressing a dominant negative ATR protein, and in primary human cells that exhibit low level of ATR activity, suggesting that the effect of pentoxifylline on HIV-1 transduction and replication is at least partly mediated by suppression of the ATR kinase.

© 2007 S. Karger AG, Basel


References

  1. Hauber I, Bevec D, Heukeshoven J, Kratzer F, Horn F, Choidas A, Harrer T, Hauber J: Identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy. J Clin Invest 2005;115:76–85.
  2. Daniel R, Kao G, Taganov K, Greger JG, Favorova O, Merkel G, Yen TJ, Katz RA, Skalka AM: Evidence that the retroviral DNA integration process triggers an ATR-dependent DNA damage response. Proc Natl Acad Sci USA 2003;100:4778–4783.
  3. Daniel R, Katz RA, Merkel G, Hittle JC, Yen TJ, Skalka AM: Wortmannin potentiates integrase-mediated killing of lymphocytes and reduces the efficiency of stable transduction by retroviruses. Mol Cell Biol 2001;21:1164–1172.
  4. Daniel R, Katz RA, Skalka AM: A role for DNA-PK in retroviral DNA integration. Science 1999;284:644–647.
  5. Daniel R, Marusich E, Argyris E, Zhao RY, Skalka AM, Pomerantz RJ: Caffeine inhibits human immunodeficiency virus type 1 transduction of nondividing cells. J Virol 2005;79:2058–2065.
  6. Lau A, Swinbank KM, Ahmed PS, Taylor DL, Jackson SP, Smith GC, O’Connor MJ: Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase. Nat Cell Biol 2005;7:493–500.
  7. Skalka AM, Katz RA: Retroviral DNA integration and the DNA damage response. Cell Death Differ 2005;12(suppl 1):971–978.
  8. Nunnari G, Argyris E, Fang J, Mehlman KE, Pomerantz RJ, Daniel R: Inhibition of HIV-1 replication by caffeine and caffeine-related methylxanthines. Virology 2005;335:177–184.
  9. Dezube BJ: Pentoxifylline for the treatment of infection with human immunodeficiency virus. Clin Infect Dis 1994;18:285–287.
  10. Biswas DK, Dezube BJ, Ahlers CM, Pardee AB: Pentoxifylline inhibits HIV-1 LTR-driven gene expression by blocking NF-kappa B action. J Acquir Immune Defic Syndr 1993;6:778–786.
  11. Clerici M, Piconi S, Balotta C, Trabattoni D, Capetti A, Fusi ML, Ruzzante S, Longhi R, Colombo MC, Moroni M, Milazzo F: Pentoxifylline improves cell-mediated immunity and reduces human immunodeficiency virus (HIV) plasma viremia in asymptomatic HIV-seropositive persons. J Infect Dis 1997;175:1210–1215.
  12. Fazely F, Dezube BJ, Allen-Ryan J, Pardee AB, Ruprecht RM: Pentoxifylline (Trental) decreases the replication of the human immunodeficiency virus type 1 in human peripheral blood mononuclear cells and in cultured T cells. Blood 1991;77:1653–1656.
  13. Mhashilkar AM, Biswas DK, LaVecchio J, Pardee AB, Marasco WA: Inhibition of human immunodeficiency virus type 1 replication in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-kappa B antagonists. J Virol 1997;71:6486–6494.
  14. Brown FL, Tahaoglu E, Graham GJ, Maio JJ: Inducible transcriptional activation of the human immunodeficiency virus long terminal repeat by protein kinase inhibitors. Mol Cell Biol 1993;13:5245–5254.
  15. Navarro J, Punzon MC, Pizarro A, Fernandez-Cruz E, Fresno M, Munoz-Fernandez MA: Pentoxifylline inhibits acute HIV-1 replication in human T cells by a mechanism not involving inhibition of tumour necrosis factor synthesis or nuclear factor-kappa B activation. AIDS 1996;10:469–475.
  16. Daniel R, Ramcharan J, Rogakou E, Taganov KD, Greger JG, Bonner W, Nussenzweig A, Katz RA, Skalka AM: Histone H2AX is phosphorylated at sites of retroviral DNA integration but is dispensable for postintegration repair. J Biol Chem 2004;279:45810–45814.
  17. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS: HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 1990;61:213–222.
  18. Butler SL, Hansen MS, Bushman FD: A quantitative assay for HIV DNA integration in vivo. Nat Med 2001;7:631–634.
  19. Wong ML, Medrano JF: Real-time PCR for mRNA quantitation. Biotechniques 2005;39:75–85.
  20. Nunnari G, Otero M, Dornadula G, Vanella M, Zhang H, Frank I, Pomerantz RJ: Residual HIV-1 disease in seminal cells of HIV-1-infected men on suppressive HAART: latency without on-going cellular infections. AIDS 2002;16:39–45.
  21. Bohm L, Roos WP, Serafin AM: Inhibition of DNA repair by pentoxifylline and related methylxanthine derivatives. Toxicology 2003;193:153–160.
  22. Sarkaria JN, Busby EC, Tibbetts RS, Roos P, Taya Y, Karnitz LM, Abraham RT: Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 1999;59:4375–4382.
  23. Brown EJ, Baltimore D: ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev 2000;14:397–402.
  24. Cortez D, Wang Y, Qin J, Elledge SJ: Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 1999;286:1162–1166.
  25. Cliby WA, Roberts CJ, Cimprich KA, Stringer CM, Lamb JR, Schreiber SL, Friend SH: Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. EMBO J 1998;17:159–169.
  26. Durocher D, Jackson SP: DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? Curr Opin Cell Biol 2001;13:225–231.
  27. O’Driscoll M, Ruiz-Perez VL, Woods CG, Jeggo PA, Goodship JA: A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nat Genet 2003;33:497–501.
  28. Goodship J, Gill H, Carter J, Jackson A, Splitt M, Wright M: Autozygosity mapping of a Seckel syndrome locus to chromosome 3q22. 1-q24. Am J Hum Genet 2000;67:498–503.
  29. Chanan-Khan A, Holkova B, Perle MA, Reich E, Wu CD, Inghirami G, Takeshita K: T-cell clonality and myelodysplasia without chromosomal fragility in a patient with features of Seckel syndrome. Haematologica 2003;88:ECR14.
  30. Andreassen PR, D’Andrea AD, Taniguchi T: ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes Dev 2004;18:1958–1963.
  31. Alderton GK, Joenje H, Varon R, Borglum AD, Jeggo PA, O’Driscoll M: Seckel syndrome exhibits cellular features demonstrating defects in the ATR-signalling pathway. Hum Mol Genet 2004;13:3127–3138.
  32. Borglum AD, Balslev T, Haagerup A, Birkebaek N, Binderup H, Kruse TA, Hertz JM: A new locus for Seckel syndrome on chromosome 18p11.31-q11.2. Eur J Hum Genet 2001;9:753–757.
  33. Faivre L, Le Merrer M, Lyonnet S, Plauchu H, Dagoneau N, Campos-Xavier AB, Attia-Sobol J, Verloes A, Munnich A, Cormier-Daire V: Clinical and genetic heterogeneity of Seckel syndrome. Am J Med Genet 2002;112:379–383.
  34. Kilinc MO, Ninis VN, Ugur SA, Tuysuz B, Seven M, Balci S, Goodship J, Tolun A: Is the novel SCKL3 at 14q23 the predominant Seckel locus? Eur J Hum Genet 2003;11:851–857.
  35. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, Luo G, Carattini-Rivera S, DeMayo F, Bradley A, Donehower LA, Elledge SJ: Chk1 is an essential kinase that is regulated by ATR and required for the G(2)/M DNA damage checkpoint. Genes Dev 2000;14:1448–1459.
  36. Dehart JL, Andersen JL, Zimmerman ES, Ardon O, An DS, Blackett J, Kim B, Planelles V: The ataxia telangiectasia-mutated and Rad3-related protein is dispensable for retroviral integration. J Virol 2005;79:1389–1396.
  37. Ariumi Y, Turelli P, Masutani M, Trono D: DNA damage sensors ATM, ATR, DNA-PKcs, and PARP-1 are dispensable for human immunodeficiency virus type 1 integration. J Virol 2005;79:2973–2978.
  38. Downs JA, Lowndes NF, Jackson SP: A role for Saccharomyces cerevisiae histone H2A in DNA repair. Nature 2000;408:1001–1004.
  39. Falck J, Coates J, Jackson SP: Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature 2005;434:605–611.
  40. Shiloh Y: ATM and ATR: networking cellular responses to DNA damage. Curr Opin Genet Dev 2001;11:71–77.
  41. Zhou BB, Elledge SJ: The DNA damage response: putting checkpoints in perspective. Nature 2000;408:433–439.
  42. Daniel R, Pomerantz RJ: ATM: HIV-1’s Achilles heel? Nat Cell Biol 2005;7:452–453.
  43. Biswas DK, Ahlers CM, Dezube BJ, Pardee AB: Pentoxifylline and other protein kinase C inhibitors down-regulate HIV-LTR NF-kappa B induced gene expression. Mol Med 1994;1:31–43.
  44. Dezube BJ, Lederman MM: Pentoxifylline for the treatment of HIV infection and its complications. J Cardiovasc Pharmacol 1995;25(suppl 2):S139–S142.
  45. Dezube BJ, Pardee AB, Chapman B, Beckett LA, Korvick JA, Novick WJ, Chiurco J, Kasdan P, Ahlers CM, Ecto LT, et al: Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. NIAID AIDS Clinical Trials Group. J Acquir Immune Defic Syndr 1993;6:787–794.
  46. Dezube BJ, Lederman MM, Spritzler JG, Chapman B, Korvick JA, Flexner C, Dando S, Mattiacci MR, Ahlers CM, Zhang L, et al: High-dose pentoxifylline in patients with AIDS: inhibition of tumor necrosis factor production. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. J Infect Dis 1995;171:1628–1632.
  47. Luke DR, McCreedy BJ, Sarnoski TP, Bookout JB, Johnston AM, Lell JE, Wiggan EB, Bell N, Limjuco RA, Guthrie KI, et al: Phase I/II study of pentoxifylline with zidovudine on HIV-1 growth in AIDS patients. Int J Clin Pharmacol Ther Toxicol 1993;31:343–350.
  48. Luke DR, Sarnoski TP, Bell N, Dennis S: Influence of pentoxifylline on renal function in HIV-seropositive patients. Ren Fail 1993;15:181–188.
  49. Wallis RS, Johnson JL, Okwera A, Nsubuga P, Whalen CC, Mugerwa RD, Ellner JJ: Pentoxifylline in human immunodeficiency virus-positive tuberculosis: safety at 4 years. J Infect Dis 1998;178:1861.
  50. Wallis RS, Nsubuga P, Whalen C, Mugerwa RD, Okwera A, Oette D, Jackson JB, Johnson JL, Ellner JJ: Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: a randomized, controlled trial. J Infect Dis 1996;174:727–733.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: January 23, 2007
Accepted: February 08, 2007
Published online: October 15, 2007
Issue release date: October 2007

Number of Print Pages: 10
Number of Figures: 6
Number of Tables: 0

ISSN: 0300-5526 (Print)
eISSN: 1423-0100 (Online)

For additional information: https://www.karger.com/INT


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.